How much does VYLOY (Zolbetuximab for Injection) Cost& price without insurance in China?
VYLOY® is the commercial brand name of Zolbetuximab for Injection, a chimeric monoclonal antibody against Claudin 18.2 developed by Astellas Pharma. It binds to Claudin 18.2 on tumor cells, mediating antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to kill cancer cells.
Main Indications
First-line treatment of adult patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that is Claudin 18.2-positive and HER2-negative, in combination with chemotherapy.
Common Side Effects
Common mild adverse reactions: Nausea, vomiting, fatigue, decreased appetite, and anemia.
Laboratory abnormalities: Decreased white blood cell count, neutropenia, and hypokalemia.
Severe but uncommon risks: Severe infusion reactions, neutropenic fever, and gastrointestinal adverse events.
Approval Status in China
VYLOY® (Zolbetuximab for Injection, 100mg per vial) was officially approved for marketing in China in 2024. It is currently a prescription anti-tumor drug.
Buy VYLOY (Zolbetuximab for Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
